EICHORCondition: Parkinson's Disease (PD) · Sponsor: AbbVie
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to continue testing whether ABBV-951 is safe, effective, and tolerable in participants with Parkinson's disease after completion of the parent study M15-741. ABBV-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (LDP/CDP) given as infusion under the skin for the treatment of Parkinson's Disease. Participants who have successfully completed M15-741 study will immediately enter this study's treatment period to continue receiving ABBV-951. Adult participants with advanced PD will be enrolled. Approximately 130 adult participants will be enrolled in the study at approximately 65 sites worldwide. Participants will receive continuous subcutaneous infusion (CSCI) of ABBV-951 for 24 hours daily during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular clinic visits and have remote assessments completed via phone calls during the course of the study. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham - Main /ID# 215597 | Birmingham, Alabama, United States | — |
| Banner Sun Health Research Institute /ID# 215579 | Sun City, Arizona, United States | — |
| University of Colorado Hospital /ID# 215625 | Aurora, Colorado, United States | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412 | Boca Raton, Florida, United States | — |
| Indiana Clinical Research Cent /ID# 216490 | Indianapolis, Indiana, United States | — |
| Univ Kansas Med Ctr /ID# 215624 | Kansas City, Kansas, United States | — |
| Washington University-School of Medicine /ID# 215472 | St Louis, Missouri, United States | — |
| Dartmouth-Hitchcock Medical Center /ID# 216834 | Lebanon, New Hampshire, United States | — |
| M3 Wake Research - Raleigh /ID# 215596 | Raleigh, North Carolina, United States | — |
| Legacy Medical Group - Neurology /ID# 215536 | Portland, Oregon, United States | — |
| Baylor College of Medicine /ID# 215401 | Houston, Texas, United States | — |
| Central Texas Neurology Consul /ID# 217013 | Round Rock, Texas, United States | — |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04379050